Put Options

2 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024

BUY
$40.88 - $43.27 $2.04 Million - $2.16 Million
50,000 Added 25.0%
250,000 $10.6 Million
Q4 2023

Feb 14, 2024

BUY
$20.27 - $42.44 $4.05 Million - $8.49 Million
200,000 New
200,000 $8.48 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Westchester Capital Management, LLC Portfolio

Follow Westchester Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Westchester Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Westchester Capital Management, LLC with notifications on news.